DRUG GUIDELINE

Direct Oral Anticoagulants (DOACs)
SCOPE (Area): (Exclude: Paediatrics Seek Advice), All Ward Areas
SCOPE (Staff): Medical, Nursing, Pharmacy
Printed versions of this document SHOULD NOT be considered up to date / current


Exclusions

Paediatrics (seek Paediatrician advice)


Preamble

See Appendix 1 for full version of this Drug Guideline


Related Documents

CPG0087 - Investigation And Initial Management Of Patients With Suspected Pulmonary Embolism in the Emergency Department
CPP0287 - Medication Administration
CPG0022 - Thromboprophylaxis
CPG0046 - Pharmacist - Referral Process For Inpatients
CPP0549 - High Risk Medications
CID0195 - Preventing Blood Clots: Information For Patients & Carers
SOP0001 - Principles Of Clinical Care


References

Alfred Health (2023, May). Therapeutic Anticoagulation with Direct-Acting Oral Anticoagulants (DOACs). Retrieved September 26, 2023 from https://app.prompt.org.au/search
CRC Press Taylor and Francis Group. (2023). Renal Drug Database. Retrieved September 26, 2023, from https://renaldrugdatabase.com/monographs
New South Wales Government, Clinical Excellence Commission (2017, July). NOAC Guidelines: Non-Vitamin K Antagonist Oral Anticoagulant. Retrieved September 26, 2023. Available from https://www.cec.health.nsw.gov.au/keep-patients-safe/medication-safety/high-risk-medicines/anticoagulants
Personal Communication with Adam Facey, Haematologist. 8th of June 2023
Queensland Health (2022, February). Anticoagulant Guideline for Hospitalised Adult Patients. Retrieved September 26, 2022. Available from https://www.health.qld.gov.au/__data../assets/pdf_file/0015/1152213/statewide-anticoagulant-guideline.pdf
Rossi, S. (2023). Australian Medicines Handbook. Retrieved September 26, 2023, from https://amhonline.amh.net.au.acs.hcn.com.au
Therapeutic Goods Administration (2023). Australian product information, Eliquis (apixaban), Pradaxa (dabigatran), Xarelto (rivaroxaban). Retrieved September 26, 2023. Available from https://www.ebs.tga.gov.au/
Therapeutic Goods Administration (2023, June). Medicines Safety Update: Oral anticoagulants can cause serious kidney damage in rare circumstances. Retrieved October 9, 2023. Available from https://www.tga.gov.au/news/safety-updates/oral-anticoagulants-can-cause-serious-kidney-damage-rare-circumstances
Therapeutic Guidelines (2023, June).Cardiovascular guidelines: Venous thromboembolism treatment. Retrieved October 18, 2023. Available from https://tgldcdp.tg.org.au.acs.hcn.com.au/etgAccess?acc=36265
University of Liverpool (2023). COVID- Drug Interactions Checker. Accessed October 2, 2023. Available from https://www.covid19-druginteractions.org/
University of Liverpool (2023, Oct). HIV Drug Interactions Checker. Accessed October 2, 2023. Available from www.hiv-druginteractions.org


Appendix

Appendix 1 - Direct Oral Anticoagulants (DOACs)



Reg Authority: Medication Safety & Governance Committee (MSGC) Date Effective: 15/11/2023
Review Responsibility: Pharmacist - Rotational Date for Review: 15/11/2026
Direct Oral Anticoagulants (DOACs) - DRG0054 - Version: 3 - (Generated On: 25-06-2025 05:45)